MedPath

Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Phase 1
Completed
Conditions
Alzheimer Disease
Huntington Disease
Interventions
First Posted Date
2009-01-29
Last Posted Date
2009-06-12
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT00831506
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin

Phase 1
Completed
Conditions
Healthy Volunteers
Pharmacokinetics
Interventions
First Posted Date
2008-07-28
Last Posted Date
2010-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
24
Registration Number
NCT00723424
Locations
🇩🇪

Research Site, Berlin, Germany

An Interaction Study With Digoxin and AZD1305

Phase 1
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2008-07-10
Last Posted Date
2010-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
18
Registration Number
NCT00712465
Locations
🇸🇪

Research Site, Göteborg, Sweden

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Phase 1
Completed
Conditions
Neoplasms, Breast
Interventions
First Posted Date
2008-04-02
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
17
Registration Number
NCT00650910
Locations
🇰🇷

GSK Investigational Site, Seoul, Korea, Republic of

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Phase 1
Conditions
Substance-Related Disorders
First Posted Date
2007-07-20
Last Posted Date
2010-10-13
Lead Sponsor
University of Washington
Target Recruit Count
20
Registration Number
NCT00504413
Locations
🇺🇸

University of Washington General Clinical Research Center, Seattle, Washington, United States

Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia

Phase 3
Completed
Conditions
Supraventricular Tachycardia
Interventions
First Posted Date
2006-10-20
Last Posted Date
2017-12-13
Lead Sponsor
University of British Columbia
Target Recruit Count
72
Registration Number
NCT00390546
Locations
🇨🇦

Hospital for Sick Kids, Toronto, Ontario, Canada

🇺🇸

University of Southern California - Children's Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

The Children's Mercy Hospital, Kansas City, Missouri, United States

and more 11 locations

Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn

Not Applicable
Completed
Conditions
Heart Diseases
First Posted Date
2000-10-05
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Registration Number
NCT00006330
Locations
🇺🇸

Univ. of Michigan Medical Center, Ann Arbor, Michigan, United States

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Phase 3
Completed
Conditions
Atrial Fibrillation
Cardiovascular Diseases
Arrhythmia
Heart Diseases
First Posted Date
1999-10-28
Last Posted Date
2016-03-25
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000556
© Copyright 2025. All Rights Reserved by MedPath